CLAUDIA VASCONCELOS (She-Her-Hers)’s Post

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/ejWZ7hMa #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/eHbNJp4M #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/ecd8kxpp #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/euD72pKc #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/eZB7hiFM #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/gAm3mt5K #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/eEQ5rkBC #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/eQQAU5rr #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/e2WPXQzs #FDA #Webinar #RareDiseases #ClinicalTrials

In 2023, over half of all the novel drugs and biologics approved by the FDA's Center for Drug Evaluation and Research (CDER) and the FDA's Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease condition. The recently formed FDA Rare Disease Innovation Hub is a new model of collaboration between #CDER and #CBER - a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases. This Parexel webinar focuses on the desired priorities and outcomes of this initiative from the perspectives of the rare disease clinical research community - including those of a clinician, former regulator and business leaders. Don't miss this webinar full of actionable insights from rare disease experts. ✅ Register now: https://lnkd.in/grkjgvjV #FDA #Webinar #RareDiseases #ClinicalTrials